Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

INTRODUCTION: No head-to-head studies have compared inotuzumab ozogamicin (InO) and blinatumomab (Blina) for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). Indirect treatment comparisons (ITCs), namely network meta-analysis (NMA), anchored ma...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Adv Ther
Huvudupphovsmän: Proskorovsky, Irina, Su, Yun, Fahrbach, Kyle, Vandendries, Erik, Pagé, Véronique, Onyekwere, Uchenna, Wang, Yunyang, Cappelleri, Joseph C., Stelljes, Matthias
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Healthcare 2019
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6822860/
https://ncbi.nlm.nih.gov/pubmed/31140123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00991-w
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk